July 31, 2017

Dynavax Technologies Corporation (NASDAQ:DVAX) announced FDA advisory committee vote in favor of Heplisav-B ™

Dynavax Technologies Corporation (NASDAQ:DVAX) announces FDA advisory committee vote in favor of Heplisav-B ™ and company also plans to launch vaccine commercially in U.S. in early 2018 on its own or through a commercial partner. The committee of Dynavax Technologies Corporation (NASDAQ:DVAX) provided commentary on design of Dynavax’s proposed post-marketing pharmacovigilance plan for Heplisav-B.

Dynavax Technologies Corporation (NASDAQ:DVAX)’s stock on Monday traded at beginning with a price of $16.95 and when day-trade ended the stock finally moved up 71.35% to reach at $15.85. Analyst’s mean target price for DVAX is $10.00 while analysts mean recommendation is 2.30. Stock value has moved between $3.2 – 17.42 in last one year.

Dynavax Technologies Corporation (NASDAQ:DVAX) yearly performance is 2.72%. Annual EPS Growth of past 5 years is 5.50%. The current share price indicates that stock is -9.43% away from its one year high and is moving 395.31% ahead of its 52-week low.

On 31 July 2017, Chevron Corporation (NYSE:CVX) stock price started the day at $108.39 and moved between $108.15 – 110.00 to finally close at $109.19. CVX’s distance from 20 day simple moving average is 4.57% and distance from 50-Day simple moving average is 4.05%. In last 4 months performance of CVX was 3.09% while its price to sale ratio is 1.71 and price to book ratio is 1.40.

Analysts expect Chevron Corporation (NYSE:CVX) to report $ 0.86 EPS and has got OUTPERFORM rating from 11 of Thomson Reuters analysts and 2 analyst(s) given UNDERPERFORM rating. Analyst’s mean target price for CVX is $122.04 while analysts mean recommendation is 2.20. Firm LT growth rate is estimated as 59.57 %.

BBVA Banco Frances S.A. (NYSE:BFR)‘s stock on Monday traded at beginning with a price of $15.85 and when day-trade ended the stock finally declined -0.57% to reach at $15.67. Analyst’s mean target price for BFR is $20.10 while analysts mean recommendation is 2.80. Stock value has moved between $15.36 – 21.76 in last one year.

Stock has got OUTPERFORM rating from 1 analyst(s) whereas last month 2 analyst(s) have given outperform rating. SELL rating has been given by 0 analyst(s) and 0 analyst(s) given BUY rating to the stock. Company fiscal year is ending in December and analysts’ consensus recommendation is Hold for BFR and estimated EPS for next quarter is $ 0.43 .

BBVA Banco Frances S.A. (NYSE:BFR) yearly performance is -22.08% and net profit margin is 18.20%. Annual EPS Growth of past 5 years is 39.10%. The current share price indicates that stock is -28.45% away from its one year high and is moving 1.69% ahead of its 52-week low.

Leave a Reply

Your email address will not be published. Required fields are marked *